急性COVID-19或儿童多系统炎症综合征患儿的补体成分水平
这项横断面研究纳入印度一家医院2020年6月至9月收治的145名1至18岁儿童,其中MIS-C 44例、急性COVID-19(RT-PCR阳性)33例、恢复期COVID-19(IgG阳性非MIS-C)47例、对照组21例。结果发现MIS-C和急性COVID-19患儿的C1q、C2、C3、C4b、C5、C5a、C3b/iC3b及B因子、D因子、H因子水平均高于恢复期和对照组儿童。MIS-C患儿的C3、C5a和甘露糖结合凝集素水平显著高于急性COVID-19患儿。部分补体分析物在入院时(即治疗前)在需要PICU支持的MIS-C患儿中更高,在发展为中重度疾病的COVID-19患儿中也更高。作者认为补体系统与儿童MIS-C和COVID-19的发病机制相关,补体抑制可作为潜在治疗选择进一步探索。
要点
- MIS-C患儿C3(318.2 [70.7] ng/mL vs 237.7 [61.8] ng/mL)、C5a(2614 [336.2] ng/mL vs 1826 [541.0] ng/mL)、甘露糖结合凝集素(79.4 [12.4] ng/mL vs 69.6 [14.7] ng/mL)水平显著高于急性COVID-19患儿。
- MIS-C与急性COVID-19患儿C1q、C2、C3、C4b、C5、C5a、C3b/iC3b及B因子、D因子、H因子水平均高于恢复期和对照组儿童。
- 入院时(即治疗前)部分补体分析物在需要PICU支持的MIS-C患儿中更高,在发展为中重度疾病的COVID-19患儿中也更高。
- 作者认为补体系统与儿童MIS-C和COVID-19的发病机制相关;补体抑制可进一步探索作为潜在治疗选择。
适用人群与场景
- 印度一家医院2020年6月至9月收治的1至18岁住院儿童,男女不限。
- 分组:MIS-C 44例、急性COVID-19(RT-PCR阳性)33例、恢复期COVID-19(IgG阳性非MIS-C)47例、对照组21例(血清学和RT-PCR均阴性)。
研究设计与关键结果
- 研究类型:横断面研究;单中心;共纳入145名儿童(中位年龄5岁[范围1个月至17岁];84名[58%]男性);数据于2022年8月分析。
- MIS-C vs 急性COVID-19 vs 对照组:C1q几何均值(SD)分别为61.5(18.5)ng/mL、56.9(18.6)ng/mL、24.1(3.3)ng/mL;C2分别为605.8(219.7)ng/mL、606.4(167.7)ng/mL、255.9(73.3)ng/mL;C3分别为318.2(70.7)ng/mL、237.7(61.8)ng/mL、123.4(15.7)ng/mL;C4b分别为712.4 ng/mL、640.7 ng/mL、351.5 ng/mL;C5分别为1487 ng/mL、1364 ng/mL、561.9 ng/mL;C5a分别为2614.0(336.2)ng/mL、1826.0(541.0)ng/mL、462.5(132.4)ng/mL;
- MIS-C患儿C3(318.2 [70.7] ng/mL vs 237.7 [61.8] ng/mL)、C5a(2614 [336.2] ng/mL vs 1826 [541.0] ng/mL)、甘露糖结合凝集素(79.4 [12.4] ng/mL vs 69.6 [14.7] ng/mL)水平显著高于急性COVID-19患儿。
- 入院时(即治疗前)部分补体分析物在需要PICU支持的MIS-C患儿中更高,在发展为中重度疾病的COVID-19患儿中也更高。
- 总体而言,MIS-C和急性COVID-19与补体成分及补体调节蛋白的过度激活相关。
证据类型、等级与局限
- 证据类型:横断面研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为补体系统与儿童MIS-C和COVID-19的发病机制相关;补体抑制可进一步探索作为潜在治疗选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Multisystem inflammatory syndrome in children (MIS-C) is a severe and unrestrained inflammatory response with multiorgan involvement, which occurs within a few weeks following the resolution of acute SARS-CoV-2 infection. The complement system is a vital part of the innate immune system and plays a role in COVID-19 pathogenesis.
OBJECTIVE: To examine and compare the levels of complement components and regulators along with complement activation products in the different clinical spectrum of children with SARS-CoV-2 and a control group.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study analyzed children with MIS-C admitted to a single hospital in India from June through September 2020. Eligible participants were children who were hospitalized of either sex, aged 1 to 18 years. Data were analyzed August 2022.
MEASURES: Levels of complement components and regulators along with complement activation products in all the groups of children. Mann-Whitney U test and Kruskal-Wallis analysis were used to compare the complement component levels, and Spearman rank correlation analysis was used to describe the association between complement components and laboratory and biochemical parameters.
RESULTS: A total 145 children were included (median age, 5 years [range, 1 month-17 years); 84 [58%] male): 44 children with MIS-C, 33 with acute COVID-19 (reverse transcriptase-polymerase chain reaction [RT-PCR] positive), 47 with convalescent COVID-19 (immunoglobulin G-positive non-MIS-C) and 21 children for a control group (both serology and RT-PCR negative). Children with MIS-C and COVID-19 had higher levels of C1q (geometric mean [SD]: MIS-C, 61.5 [18.5] ng/mL; acute COVID-19, 56.9 [18.6] ng/mL; controls, 24.1 [3.3] ng/mL), C2 (MIS-C, 605.8 [219.7] ng/mL; acute COVID-19, 606.4 [167.7] ng/mL; controls, 255.9 [73.3] ng/mL), C3 (MIS-C, 318.2 [70.7] ng/mL; acute COVID-19, 237.7 [61.8] ng/mL; controls, 123.4 [15.7] ng/mL), C4b (MIS-C, 712.4 ng/mL; acute COVID-19, 640.7 ng/mL; controls, 351.5 ng/mL), C5 (MIS-C, 1487 ng/mL; acute COVID-19, 1364 ng/mL; controls, 561.9 ng/mL), C5a, (MIS-C, 2614.0 [336.2] ng/mL; acute COVID-19, 1826.0 [541.0] ng/mL; controls, 462.5 [132.4] ng/mL), C3b/iC3b (MIS-C, 3971.0 [635.1] ng/mL; acute COVID-19, 3702.0 [653.9] ng/mL; controls, 2039.0 [344.5] ng/mL), and factor B (MIS-C, 47.6 [7.8] ng/mL; acute COVID-19, 44.6 [6.3] ng/mL; controls, 27.5 [5.0] ng/mL), factor D (MIS-C, 44.0 [17.2] ng/mL; acute COVID-19, 33.8 [18.4] ng/mL; controls, 21.3 [6.1] ng/mL), and factor H (MIS-C, 53.1 [4.0] ng/mL; acute COVID-19, 50.8 [5.7] ng/mL; controls, 43.6 [3.8] ng/mL) in comparison with convalescent and control children. In addition, children with MIS-C had significantly elevated levels of C3 (318.2 [70.7] ng/mL vs 237.7 [61.8] ng/mL), C5a (2614 [336.2] ng/mL vs 1826 [541.0] ng/mL), and mannose-binding lectin (79.4 [12.4] ng/mL vs 69.6 [14.7] ng/mL) in comparison to children with acute COVID-19. Levels of some of these analytes at admission (ie, pretreatment) were more elevated in children with MIS-C who needed pediatric intensive care unit (PICU) support as compared with those who did not require PICU support, and in children with COVID-19 who developed moderate to severe disease compared with those who developed mild disease. Overall, MIS-C and acute COVID-19 were associated with the hyperactivation of complement components and complement regulators.
CONCLUSIONS AND RELEVANCE: In this cross-sectional study, the complement system was associated with the pathogenesis of MIS-C and COVID-19 in children; complement inhibition could be further explored as a potential treatment option.
参考来源
- Rajamanickam A, Nathella PK, Venkataraman A, et al. Levels of Complement Components in Children With Acute COVID-19 or Multisystem Inflammatory Syndrome. JAMA Netw Open. 2023. PMID: 36961465. doi:10.1001/jamanetworkopen.2023.1713
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。